They are writing an article for submission to a journal. This, of course, addresses one of the stupid complaints the bashers have made -- that there hasn't been any publication. (Not publishing is perfectly normal for a biotech, especially a small biotech.) My own theory, which is a GUESS based on zero information except deductive reasoning, is that the reason Dana-Farber wanted to extend Phase 1 was that there was some other data they wanted to collect before writing the article.

Someone involved in a pioneering treatment for cancer, working by turning the body's own defensive gene back on, is looking at a LOT of fame here. You can bet that the person writing the article, presumably Dr. Shapiro of Dana-Farber, wants everything to be perfect for submission. And also, this means that there will be NO release of data until the article is out. Who wants to be "old news" when they publish ground-breaking material? People would just skim the article if they bothered to read it at all, if the data is already out.

So the short answer is: the data most likely will be out when the article is accepted and published.

IN MY OPINION WHICH COULD BE WRONG